期刊
EXPERT OPINION ON THERAPEUTIC PATENTS
卷 21, 期 3, 页码 424-429出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543776.2011.536533
关键词
allergic rhinitis; GlaxoSmithKline; H-1 antagonist; H-3 antagonist; histamine
This application claims dual receptor specificity antihistamines, active as H-1 and H-3 antagonists, which additionally have a long duration of action that renders them suitable for once daily administration via inhalation for the treatment of allergic rhinitis. The compounds lack CNS penetration and have a high affinity for both histamine receptors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据